| abstract |
In the present invention there are disclosed derivatives of 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one of the general formula I in which Ri1 represents alkyl containing 1 to 4 carbon atoms or cycloalkylmethyl containing 3 to 7 carbon atoms in the cycloalkyl moiety, Xi1 represents hydrogen or a halogen or alkoxyl containing 1 to 4 carbon atoms, or the radicals ORi1 and Xi1 together represent the group -OCHi2O-, -O(CHi2)i2-, -O(CHi2)i3O-, -O(CHi2)i2O- or -O(CHi2)i3O-, Xi2 represents hydrogen or an amino group, Xi3 represents hydrogen or a halogen and Ri2 represents hydrogen, or an optionally substituted alkyl containing 1 to 6 carbon atoms or phenylalkyl containing 1 to 4 carbon atoms in the alkyl moiety being optionally substituted on a phenyl ring or phenylalkenyl having 2 to 3 carbon atoms in the alkenyl moiety phenoxyalkyl containing 2 to 4 carbon atoms in the alkyl moiety, or cycloalkylmethyl with 3 to 7 carbon atoms in the cycloalkyl moiety or 2,3-dihydro-1H-inden-1-yl, or 2,3-dihydro-1H-inden-2-yl, or the group of the general formula -(CHi2)inCO-Z wherein n is a number ranging from 1 to 6 and Z represents piperidin-1-yl or 4- (dimethylamino)piperidin-1-yl, and which can be used in therapy. In the present invention there is also claimed a process of their preparation as well as pharmaceutical preparation in which they are comprised. |